These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26521853)

  • 1. Novel Tranylcypromine/Hydroxylcinnamic Acid Hybrids as Lysine-Specific Demethylase 1 Inhibitors with Potent Antitumor Activity.
    Han Y; Wu C; Lv H; Liu N; Deng H
    Chem Pharm Bull (Tokyo); 2015; 63(11):882-9. PubMed ID: 26521853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
    Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
    Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
    Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
    Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blasts.
    Valente S; Rodriguez V; Mercurio C; Vianello P; Saponara B; Cirilli R; Ciossani G; Labella D; Marrocco B; Monaldi D; Ruoppolo G; Tilset M; Botrugno OA; Dessanti P; Minucci S; Mattevi A; Varasi M; Mai A
    Eur J Med Chem; 2015 Apr; 94():163-74. PubMed ID: 25768700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of tranylcypromine analogs with an acylhydrazone substituent as LSD1 inactivators: Design, synthesis and their biological evaluation.
    Sun K; Peng JD; Suo FZ; Zhang T; Fu YD; Zheng YC; Liu HM
    Bioorg Med Chem Lett; 2017 Nov; 27(22):5036-5039. PubMed ID: 29037950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor.
    Wang X; Su M; Li Y; Liu T; Wang Y; Chen Y; Tang L; He YP; Ding X; Yu F; Shen J; Li J; Zhou Y; Chen YL; Xiong B
    Bioorg Med Chem Lett; 2019 Mar; 29(6):844-847. PubMed ID: 30713023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of Carboxamide-Containing Tranylcypromine Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia.
    Teresa Borrello M; Benelkebir H; Lee A; Hin Tam C; Shafat M; Rushworth SA; Bowles KM; Douglas L; Duriez PJ; Bailey S; Crabb SJ; Packham G; Ganesan A
    ChemMedChem; 2021 Apr; 16(8):1316-1324. PubMed ID: 33533576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
    Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM
    Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
    Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
    Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors.
    Benelkebir H; Hodgkinson C; Duriez PJ; Hayden AL; Bulleid RA; Crabb SJ; Packham G; Ganesan A
    Bioorg Med Chem; 2011 Jun; 19(12):3709-16. PubMed ID: 21382717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors.
    Huang MJ; Guo JW; Fu YD; You YZ; Xu WY; Song TY; Li R; Chen ZT; Huang LH; Liu HM
    Bioorg Med Chem Lett; 2021 Jun; 41():127993. PubMed ID: 33775841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorinated tranylcypromine analogues as inhibitors of lysine-specific demethylase 1 (LSD1, KDM1A).
    Borrello MT; Schinor B; Bartels K; Benelkebir H; Pereira S; Al-Jamal WT; Douglas L; Duriez PJ; Packham G; Haufe G; Ganesan A
    Bioorg Med Chem Lett; 2017 May; 27(10):2099-2101. PubMed ID: 28390942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. cis-Cyclopropylamines as mechanism-based inhibitors of monoamine oxidases.
    Malcomson T; Yelekci K; Borrello MT; Ganesan A; Semina E; De Kimpe N; Mangelinckx S; Ramsay RR
    FEBS J; 2015 Aug; 282(16):3190-8. PubMed ID: 25755053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 .
    Mimasu S; Umezawa N; Sato S; Higuchi T; Umehara T; Yokoyama S
    Biochemistry; 2010 Aug; 49(30):6494-503. PubMed ID: 20568732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation.
    Fioravanti R; Romanelli A; Mautone N; Di Bello E; Rovere A; Corinti D; Zwergel C; Valente S; Rotili D; Botrugno OA; Dessanti P; Vultaggio S; Vianello P; Cappa A; Binda C; Mattevi A; Minucci S; Mercurio C; Varasi M; Mai A
    ChemMedChem; 2020 Apr; 15(7):643-658. PubMed ID: 32003940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment.
    Ma QS; Zhang YF; Li CY; Zhang WX; Yuan L; Niu JB; Song J; Zhang SY; Liu HM
    Eur J Med Chem; 2023 May; 251():115228. PubMed ID: 36881982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent.
    Vianello P; Botrugno OA; Cappa A; Dal Zuffo R; Dessanti P; Mai A; Marrocco B; Mattevi A; Meroni G; Minucci S; Stazi G; Thaler F; Trifiró P; Valente S; Villa M; Varasi M; Mercurio C
    J Med Chem; 2016 Feb; 59(4):1501-17. PubMed ID: 26702542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2.
    Binda C; Valente S; Romanenghi M; Pilotto S; Cirilli R; Karytinos A; Ciossani G; Botrugno OA; Forneris F; Tardugno M; Edmondson DE; Minucci S; Mattevi A; Mai A
    J Am Chem Soc; 2010 May; 132(19):6827-33. PubMed ID: 20415477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterocycle-containing tranylcypromine derivatives endowed with high anti-LSD1 activity.
    Fioravanti R; Rodriguez V; Caroli J; Chianese U; Benedetti R; Di Bello E; Noce B; Zwergel C; Corinti D; Viña D; Altucci L; Mattevi A; Valente S; Mai A
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):973-985. PubMed ID: 35317680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents.
    Ma LY; Zheng YC; Wang SQ; Wang B; Wang ZR; Pang LP; Zhang M; Wang JW; Ding L; Li J; Wang C; Hu B; Liu Y; Zhang XD; Wang JJ; Wang ZJ; Zhao W; Liu HM
    J Med Chem; 2015 Feb; 58(4):1705-16. PubMed ID: 25610955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.